Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

From germ theory to germ therapy.

Chen CC, Chen YN, Liou JM, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium.

Kaohsiung J Med Sci. 2019 Feb;35(2):73-82. doi: 10.1002/kjm2.12011. Review.

2.

Toward population specific and personalized treatment of Helicobacter pylori infection.

Liou JM, Chen PY, Kuo YT, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium.

J Biomed Sci. 2018 Oct 2;25(1):70. doi: 10.1186/s12929-018-0471-z. Review.

3.

Systematic review and network meta-analysis: Comparative effectiveness of therapies for second-line Helicobacter pylori eradication.

Yeo YH, Hsu CC, Lee CC, Ho HJ, Lin JT, Wu MS, Liou JM, Wu CY; Taiwan Gastrointestinal Disease and Helicobacter Consortium.

J Gastroenterol Hepatol. 2019 Jan;34(1):59-67. doi: 10.1111/jgh.14462. Epub 2018 Oct 11.

PMID:
30169908
4.

Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection.

Liou JM, Chen PY, Luo JC, Lee JY, Chen CC, Fang YJ, Yang TH, Chang CY, Bair MJ, Chen MJ, Hsu YC, Hsu WF, Chang CC, Lin JT, Shun CT, El-Omar EM, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium.

Gastroenterology. 2018 Oct;155(4):1109-1119. doi: 10.1053/j.gastro.2018.06.047. Epub 2018 Jun 30.

PMID:
29964036
5.

Impact of amoxicillin resistance on the efficacy of amoxicillin-containing regimens for Helicobacter pylori eradication: analysis of five randomized trials.

Chen MJ, Wu MS, Chen CC, Chen CC, Fang YJ, Bair MJ, Chang CY, Lee JY, Hsu WF, Luo JC, Lin JT, Liou JM; Taiwan Gastrointestinal Disease and Helicobacter Consortium.

J Antimicrob Chemother. 2017 Dec 1;72(12):3481-3489. doi: 10.1093/jac/dkx320.

PMID:
28961996
6.

Distinct Clinicopathological Features and Prognosis of Helicobacter pylori Negative Gastric Cancer.

Tsai KF, Liou JM, Chen MJ, Chen CC, Kuo SH, Lai IR, Yeh KH, Lin MT, Wang HP, Cheng AL, Lin JT, Shun CT, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium.

PLoS One. 2017 Feb 2;12(2):e0170942. doi: 10.1371/journal.pone.0170942. eCollection 2017.

7.

Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.

Liou JM, Fang YJ, Chen CC, Bair MJ, Chang CY, Lee YC, Chen MJ, Chen CC, Tseng CH, Hsu YC, Lee JY, Yang TH, Luo JC, Chang CC, Chen CY, Chen PY, Shun CT, Hsu WF, Hu WH, Chen YN, Sheu BS, Lin JT, Wu JY, El-Omar EM, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium.

Lancet. 2016 Nov 12;388(10058):2355-2365. doi: 10.1016/S0140-6736(16)31409-X. Epub 2016 Oct 18.

PMID:
27769562
8.

First-line Helicobacter pylori eradication therapies in countries with high and low clarithromycin resistance: a systematic review and network meta-analysis.

Yeo YH, Shiu SI, Ho HJ, Zou B, Lin JT, Wu MS, Liou JM, Wu CY; Taiwan Gastrointestinal Disease and Helicobacter Consortium.

Gut. 2018 Jan;67(1):20-27. doi: 10.1136/gutjnl-2016-311868. Epub 2016 Sep 26. Review.

PMID:
27670375
9.

Systematic review with meta-analysis: the efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection.

Chen PY, Wu MS, Chen CY, Bair MJ, Chou CK, Lin JT, Liou JM; Taiwan Gastrointestinal Disease and Helicobacter Consortium.

Aliment Pharmacol Ther. 2016 Sep;44(5):427-37. doi: 10.1111/apt.13712. Epub 2016 Jun 30. Review.

10.

Levofloxacin Sequential Therapy vs Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori: A Randomized Trial.

Liou JM, Bair MJ, Chen CC, Lee YC, Chen MJ, Chen CC, Tseng CH, Fang YJ, Lee JY, Yang TH, Luo JC, Wu JY, Chang WH, Chang CC, Chen CY, Chen PY, Shun CT, Hsu WF, Hung HW, Lin JT, Chang CY, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium.

Am J Gastroenterol. 2016 Mar;111(3):381-7. doi: 10.1038/ajg.2015.439. Epub 2016 Feb 2.

PMID:
26832653
11.

Systematic review with meta-analysis: 10- or 14-day sequential therapy vs. 14-day triple therapy in the first line treatment of Helicobacter pylori infection.

Liou JM, Chen CC, Lee YC, Chang CY, Wu JY, Bair MJ, Lin JT, Chen MJ, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium.

Aliment Pharmacol Ther. 2016 Feb;43(4):470-81. doi: 10.1111/apt.13495. Epub 2015 Dec 15. Review.

12.

Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trial.

Liou JM, Chen CC, Chang CY, Chen MJ, Chen CC, Fang YJ, Lee JY, Yang TH, Luo JC, Wu JY, Liou TC, Chang WH, Hsu YC, Tseng CH, Chang CC, Bair MJ, Liu TY, Hsieh CF, Tsao FY, Shun CT, Lin JT, Lee YC, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium.

Gut. 2016 Nov;65(11):1784-1792. doi: 10.1136/gutjnl-2015-310142. Epub 2015 Sep 3.

13.

The Primary Resistance of Helicobacter pylori in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factors-A Nationwide Study.

Liou JM, Chang CY, Chen MJ, Chen CC, Fang YJ, Lee JY, Wu JY, Luo JC, Liou TC, Chang WH, Tseng CH, Wu CY, Yang TH, Chang CC, Wang HP, Sheu BS, Lin JT, Bair MJ, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium.

PLoS One. 2015 May 5;10(5):e0124199. doi: 10.1371/journal.pone.0124199. eCollection 2015.

14.

Distinct aetiopathogenesis in subgroups of functional dyspepsia according to the Rome III criteria.

Fang YJ, Liou JM, Chen CC, Lee JY, Hsu YC, Chen MJ, Tseng PH, Chen CC, Chang CY, Yang TH, Chang WH, Wu JY, Wang HP, Luo JC, Lin JT, Shun CT, Wu MS; Taiwan Gastrointestinal Disease and Helicobacter Consortium.

Gut. 2015 Oct;64(10):1517-28. doi: 10.1136/gutjnl-2014-308114. Epub 2014 Nov 18.

15.

A tool to predict risk for gastric cancer in patients with peptic ulcer disease on the basis of a nationwide cohort.

Lee TY, Wang CB, Chen TT, Kuo KN, Wu MS, Lin JT, Wu CY; Taiwan Gastrointestinal Disease and Helicobacter Consortium.

Clin Gastroenterol Hepatol. 2015 Feb;13(2):287-293.e1. doi: 10.1016/j.cgh.2014.07.043. Epub 2014 Jul 30.

PMID:
25083561

Supplemental Content

Loading ...
Support Center